Von Willebrand disease: Difference between revisions
(→Source) |
Timothydavie (talk | contribs) No edit summary |
||
Line 34: | Line 34: | ||
==Source== | ==Source== | ||
Tintinalli | Tintinalli's Emergency Medicine: A Comprehensive Study Guide, 7e (2010), Chapter 230. Hemophilias and Von Willbrand Disease | ||
Uptodate | Uptodate | ||
[[Category:Heme/Onc]] | [[Category:Heme/Onc]] |
Revision as of 06:05, 10 April 2013
Background
- Most common inherited bleeding disorder
- vWF has two roles:
- 1. Acts as cofactor for platelet adhesion
- 2. Acts as carrier protein for factor VIII extending its half life
- vWD results from quantitative or qualitative dysfunction of Von Willebrand factor
Clinical Features
- Skin and mucosal bleeding
- Epistaxis, gingival bleeding, menorrhagia
- Hemarthrosis is unusual
Diagnosis
- Bleeding time: prolonged
- PT: normal
- PTT: normal-mildly prolonged
- vWF activity level: low
Treatment
- Avoid ASA, NSAIDs, heparin
- Intermediate purity factor VIII
- Goal to increase VWF activity by 50-100%
- Initial infusion of 20-40 IU/Kg
- High replacement doses may be indicated in more severe disease
- Platelet transfusion
- consider if replacement therapy instituted and persistent bleeding
- Desmopressin
- Induces release of vWF from endothelial storage sites
- 0.3mcg/kg IV (max 20mcg) over 30min
- Aminocaproic acid
- Recombinant Factor VIIa
- Consider in type 3 VWD patients who have developed antibodies to VWF replacement
- Increased risk of thrombosis, especially in patients with coronary artery disease
Source
Tintinalli's Emergency Medicine: A Comprehensive Study Guide, 7e (2010), Chapter 230. Hemophilias and Von Willbrand Disease Uptodate